Shattuck Labs (NASDAQ:STTK) Research Coverage Started at Evercore ISI

Evercore ISI initiated coverage on shares of Shattuck Labs (NASDAQ:STTK) in a research note published on Monday, Analyst Ratings Network reports. The brokerage issued an outperform rating on the stock.

STTK has been the topic of several other reports. Cowen initiated coverage on shares of Shattuck Labs in a report on Tuesday, November 3rd. They issued an outperform rating on the stock. Needham & Company LLC began coverage on shares of Shattuck Labs in a research note on Tuesday, November 3rd. They issued a buy rating and a $34.00 price target on the stock. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell initiated coverage on shares of Shattuck Labs in a report on Tuesday, November 3rd. They issued a buy rating and a $36.00 price objective for the company. Finally, Smith Barney Citigroup began coverage on shares of Shattuck Labs in a report on Tuesday, November 3rd. They set a buy rating and a $36.00 price target for the company. Five analysts have rated the stock with a buy rating, Shattuck Labs has a consensus rating of Buy and an average price target of $35.33.

STTK stock opened at $47.35 on Monday. Shattuck Labs has a 1 year low of $17.51 and a 1 year high of $60.52. The business has a fifty day moving average price of $42.10.

Shattuck Labs (NASDAQ:STTK) last posted its quarterly earnings results on Friday, November 13th. The company reported ($1.54) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.35) by ($1.19). The business had revenue of $2.44 million during the quarter.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian cancer. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma.

Read More: Systematic Risk and Investors

Analyst Recommendations for Shattuck Labs (NASDAQ:STTK)

Receive News & Ratings for Shattuck Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shattuck Labs and related companies with MarketBeat.com's FREE daily email newsletter.